Burning Rock Biotech/BNR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Burning Rock Biotech

Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.

Ticker

BNR

Sector

Healthcare

Trading on

NASDAQ

Industry

Healthcare Facilities

CEO

Yansheng Han

Employees

786

Headquarters

Guangzhou, China

BNR Metrics

BasicAdvanced
$73M
Market cap
-
P/E ratio
-$64.81
EPS
0.18
Beta
-
Dividend rate
$73M
0.1809
$26.20
$5.72
4.6K
3.292
3.045
-49.12%
-66.95%
-65.97%
1.02
0.74
0.742
-8.71%
45.74%
7.73%

BNR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-96.73% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
¥126M
3.80%
Net income
-¥122M
-25.09%
Profit margin
-96.73%
-27.83%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Burning Rock Biotech stock?

Burning Rock Biotech (BNR) has a market cap of $73M as of June 17, 2024.

What is the P/E ratio for Burning Rock Biotech stock?

The price to earnings (P/E) ratio for Burning Rock Biotech (BNR) stock is 0 as of June 17, 2024.

Does Burning Rock Biotech stock pay dividends?

No, Burning Rock Biotech (BNR) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next Burning Rock Biotech dividend payment date?

Burning Rock Biotech (BNR) stock does not pay dividends to its shareholders.

What is the beta indicator for Burning Rock Biotech?

Burning Rock Biotech (BNR) has a beta rating of 0.18. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Burning Rock Biotech stock price target?

The target price for Burning Rock Biotech (BNR) stock is $, which is NaN% below the current price of $. This is an average based on projections from analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Burning Rock Biotech stock

Buy or sell Burning Rock Biotech stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing